RECRUITING

Pancreatic Cancer Early Detection Consortium

Description

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Conditions

Pancreas CancerPancreas CystPancreatic Ductal AdenocarcinomaGenetic Predisposition
Talk to us

Related Conditions:

Pancreas CancerPancreas CystPancreatic Ductal AdenocarcinomaGenetic Predisposition

Study Overview

On this page

Study Details

Study overview

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Pancreatic Cancer Early Detection Consortium

Pancreatic Cancer Early Detection Consortium

Condition
Pancreas Cancer
Intervention / Treatment

-

Contacts and Locations

Phoenix

Mayo Clinic Arizona, Phoenix, Arizona, United States, 85054

Scottsdale

Honor Health Research Institute, Scottsdale, Arizona, United States, 85258

Burbank

Providence Health and Services, Burbank, California, United States, 91505

Duarte

City of Hope, Duarte, California, United States, 91010

La Jolla

UC San Diego Moores Cancer Center, La Jolla, California, United States, 92093

Los Angeles

Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048

Los Angeles

UCLA Health, Los Angeles, California, United States, 90095

Orange

UC Irvine Health, Orange, California, United States, 92868

Sacramento

UC Davis, Sacramento, California, United States, 95817

San Francisco

University of California, San Francisco (UCSF), San Francisco, California, United States, 94143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.
  • 2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family
  • 3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family
  • 4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+
  • 5. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+
  • 6. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+
  • 1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+
  • 2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family
  • 3. 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member
  • 1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
  • 2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
  • 3. Diagnosed ≤ age 45
  • * Individuals not meeting the criteria above.

Ages Eligible for Study

18 Years to 90 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Arbor Research Collaborative for Health,

Diane Simeone, MD, STUDY_CHAIR, UC San Diego Moores Cancer Center

Study Record Dates

2030-12-31